Equinix Inc (EQIX)vsEdwards Lifesciences Corp (EW)
EQIX
Equinix Inc
$1,089.07
+1.18%
REAL ESTATE · Cap: $106.79B
EW
Edwards Lifesciences Corp
$81.22
-1.29%
HEALTHCARE · Cap: $46.83B
Smart Verdict
WallStSmart Research — data-driven comparison
Equinix Inc generates 47% more annual revenue ($9.26B vs $6.30B). EW leads profitability with a 17.4% profit margin vs 14.6%. EW appears more attractively valued with a PEG of 2.02. EW earns a higher WallStSmart Score of 61/100 (C+).
EQIX
Buy50
out of 100
Grade: C-
EW
Buy61
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-38.5%
Fair Value
$626.41
Current Price
$1089.07
$462.66 premium
Margin of Safety
+70.0%
Fair Value
$264.83
Current Price
$81.22
$183.61 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Large-cap with strong market position
Strong operational efficiency at 21.5%
Earnings expanding 22.9% YoY
Strong operational efficiency at 31.2%
16.7% revenue growth
Areas to Watch
Elevated debt levels
Weak financial health signals
Expensive relative to growth rate
Premium valuation, high expectations priced in
Expensive relative to growth rate
Weak financial health signals
Premium valuation, high expectations priced in
Comparative Analysis Report
WallStSmart ResearchBull Case : EQIX
The strongest argument for EQIX centers on Market Cap, Operating Margin, EPS Growth.
Bull Case : EW
The strongest argument for EW centers on Operating Margin, Revenue Growth. Profitability is solid with margins at 17.4% and operating margin at 31.2%. Revenue growth of 16.7% demonstrates continued momentum.
Bear Case : EQIX
The primary concerns for EQIX are Debt/Equity, Piotroski F-Score, PEG Ratio. A P/E of 74.6x leaves little room for execution misses. Debt-to-equity of 1.61 is elevated, increasing financial risk.
Bear Case : EW
The primary concerns for EW are PEG Ratio, Piotroski F-Score, P/E Ratio. A P/E of 43.9x leaves little room for execution misses.
Key Dynamics to Monitor
EQIX profiles as a value stock while EW is a growth play — different risk/reward profiles.
EQIX carries more volatility with a beta of 1.00 — expect wider price swings.
EW is growing revenue faster at 16.7% — sustainability is the question.
EW generates stronger free cash flow (354M), providing more financial flexibility.
Bottom Line
EW scores higher overall (61/100 vs 50/100), backed by strong 17.4% margins and 16.7% revenue growth. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Equinix Inc
REAL ESTATE · REIT - SPECIALTY · USA
Equinix, Inc. is an American multinational company headquartered in Redwood City, California, that specializes in Internet connection and data centers.
Visit Website →Edwards Lifesciences Corp
HEALTHCARE · MEDICAL DEVICES · USA
Edwards Lifesciences is an American medical technology company headquartered in Irvine, California, specializing in artificial heart valves and hemodynamic monitoring.
Visit Website →Compare with Other REIT - SPECIALTY Stocks
Want to dig deeper into these stocks?